Credit Agricole
ALXN

Credit Agricole’s Alexion Pharmaceuticals ALXN Stock Holding History

Credit Agricole’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-448
Closed -$69K – 774
2021
Q1 		$69K Sell
448
-80
-15% -$12.4K ﹤0.01% 420
2020
Q4 		$82K Buy
528
+28
+6% +$3.6K ﹤0.01% 360
2020
Q3 		$57K Hold
500
– – ﹤0.01% 358
2020
Q2 		$56K Hold
500
– – ﹤0.01% 322
2020
Q1 		$45K Buy
500
+100
+25% +$9.81K ﹤0.01% 326
2019
Q4 		$43K Hold
400
– – ﹤0.01% 324
2019
Q3 		$39K Hold
400
– – ﹤0.01% 390
2019
Q2 		$52K Hold
400
– – ﹤0.01% 374
2019
Q1 		$54K Buy
+400
New +$49.7K ﹤0.01% 380
2018
Q4 		– Sell
-246
Closed -$34K – 513
2018
Q3 		$34K Hold
246
– – ﹤0.01% 389
2018
Q2 		$31K Buy
+246
New +$28.8K ﹤0.01% 349
2017
Q4 		– Sell
-266,204
Closed -$37.3M – 1218
2017
Q3 		$37.3M Buy
266,204
+182,887
+220% +$24.8M 0.13% 187
2017
Q2 		$10.1M Buy
83,317
+14,151
+20% +$1.65M 0.03% 492
2017
Q1 		$8.38M Buy
69,166
+6,524
+10% +$841K 0.03% 611
2016
Q4 		$7.67M Buy
62,642
+12,410
+25% +$1.52M 0.02% 562
2016
Q3 		$6.16M Sell
50,232
-11,806
-19% -$1.52M 0.02% 621
2016
Q2 		$7.24M Buy
62,038
+4,517
+8% +$641K 0.03% 529
2016
Q1 		$8.01M Buy
57,521
+2,514
+5% +$369K 0.04% 441
2015
Q4 		$10.5M Buy
55,007
+14,161
+35% +$2.47M 0.05% 363
2015
Q3 		$6.39M Buy
40,846
+3,077
+8% +$561K 0.03% 499
2015
Q2 		$6.83M Sell
37,769
-14,292
-27% -$2.47M 0.03% 509
2015
Q1 		$9.02M Sell
52,061
-1,729
-3% -$313K 0.04% 452
2014
Q4 		$10.1M Buy
53,790
+7,365
+16% +$1.36M 0.04% 431
2014
Q3 		$7.7M Buy
46,425
+2,306
+5% +$379K 0.03% 496
2014
Q2 		$6.89M Sell
44,119
-2,590
-6% -$409K 0.03% 537
2014
Q1 		$7.11M Sell
46,709
-11,596
-20% -$1.84M 0.03% 521
2013
Q4 		$7.75M Sell
58,305
-33,344
-36% -$4M 0.03% 522
2013
Q3 		$10.6M Buy
+91,649
New +$10.1M 0.05% 415

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Credit Agricole's ALXN Position: Q2 2021 in Review

Credit Agricole sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 448 shares — an estimated $69K sold.

Credit Agricole first reported a position in ALXN in Q3 2013 and held it in 28 quarters. The position peaked at $37.3M in Q3 2017. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Credit Agricole reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Credit Agricole sold 448 Alexion Pharmaceuticals shares in Q2 2021, an estimated $69K.
  • Credit Agricole first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 28 quarters.
  • Credit Agricole's Alexion Pharmaceuticals position peaked at $37.3M in Q3 2017.
  • 710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Credit Agricole's 13F filing for Q2 2021, filed 10 Aug 2021.